Cue Biopharma, a clinical-stage biopharmaceutical company, announced a $50 million private placement by selling 1.4 million shares and pre-funded warrants to accredited investors at about $33.21 per share. The funding, led by Cormorant Asset Management and including Columbia Threadneedle Investments, will support Cue's clinical development and general corporate needs. The company is advancing therapies targeting functional cures for immunological disorders, with upcoming clinical data expected by Q3 2026. The private placement is expected to close around July 13, 2026, subject to customary conditions.
The 2026 Global Health Congress in New York gathered over 625 healthcare leaders from 25 countries to discuss innovation, equity, and investment in healthcare. The event featured 350+ startup applications in its Healthcare Shark Tank competition, cro...
Ambarella, an edge AI semiconductor company, announced its third quarter fiscal year 2027 earnings conference call will be held on November 24, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report after the market closes that...
Cenovus Energy is experiencing a widened discount to light oil, reaching $31.70, which will affect its fourth quarter results in fiscal year 2026. Management attributes this discount expansion mainly to temporary freight costs and is sticking to its ...
U.S. spot Bitcoin ETFs experienced net outflows of $430.20 million on November 5, reversing the previous day's inflows of $74.57 million. Six of the twelve funds, including Fidelity’s FBTC and BlackRock’s IBIT, saw significant withdrawals. Total trad...
Macro analyst Roberto Rios predicts Bitcoin will reach $300,000 during the current market cycle, citing unexpected strength since a June low. He explains that the market is factoring in increased money creation by the Federal Reserve and further weak...
